<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">  <head>    <meta http-equiv="Content-Type" content="text/html; charset=UTF-8"/>    <title>All Interactions with Tenofovir disoproxil fumarate</title><link rel="stylesheet" href="css/insite.css" type="text/css"/><link rel="stylesheet" href="css/layout.css" type="text/css"/><link rel="stylesheet" href="css/topNav.css" type="text/css"/><!-- jquery javascript --><script type="text/javascript" src="script/jquery/load.js"><!--  --></script><script type="text/javascript" src="app-js/jquery.scrollTo.js"> </script><script type="text/javascript" src="app-js/jquery.cycle.js"> </script><script type="text/javascript" language="JavaScript">
        function openWindow(url,name){
            newWin = window.open(url,name,'status,toolbar,menubar,resizable,scrollbars,left=20,top=20,width=650,height=600')
            newWin.focus()
        }

        function openXWindow(url,name){
            newXWin = window.open(url,name)
            newXWin.focus()
        }

		/* BASED ON NEC DEMO.XML */
		   // REVEAL HIDDEN LOGIC QUESTION
				function branchNext (event) {
					$.log("BRANCHNEXT() :  enter");
					var n = $(this).children("input:checked").size();

					if (n)   {
						 var reveal = "." + $($(this).children("input:checked")).attr("name") + "-" + $($(this).children("input:checked")).val();

						 $(reveal).removeClass("hidden").addClass("question-revealed");
					}
			   }

		// HIDE TO-BE-REVEALED LOGIC QUESTIONS
			$(document).ready(function() { hideLogicQuestions($(document).children()[0]) });

			function hideLogicQuestions (element) {
				$.log("hideLogicQuestions() : enter");
				$(".hidden-question").each(function() {
					$(this).addClass("hidden").removeClass("question-revealed");
				});
		   }
		/* END FROM NEC DEMO.XML */


			function expand(event)
			{
				var id = $(event.target).attr("query");
				var section = $("#" + id);

				/* CLOSE ALL SECTIONS AND RESET BUTTONS
				$(".expandable", section).addClass("hidden");
				$(".expand", section).removeClass("hidden");
				$(".collapse", section).addClass("hidden");
				$(".expandAll", section).removeClass("hidden");
				$(".collapseAll", section).addClass("hidden");
				*/

				// OPEN SPECIFIED SECTION AND UPDATE ITS BUTTONS
				section.removeClass("hidden");
				$(this).addClass("hidden");
				$(this).siblings(".collapse").removeClass("hidden");

				// $(this).siblings(".expandAll").addClass("hidden");
				// $(this).siblings(".collapseAll").removeClass("hidden");
			}
			function collapse(event)
			{
				var id = $(event.target).attr("query");
				var section = $("#" + id);

				section.addClass("hidden");
				$(this).addClass("hidden");
				$(this).siblings(".expand").removeClass("hidden");

				$(this).siblings(".collapseAll").addClass("hidden");
				$(this).siblings(".expandAll").removeClass("hidden");
			}

			function expandAll(event)
			{
				var id = $(event.target).attr("query");
				var section = $("#" + id);

				section.removeClass("hidden");
				$(".expandable", section).removeClass("hidden");
				$(this).addClass("hidden");

				$(this).siblings(".expand").addClass("hidden");
				$(this).siblings(".collapse").removeClass("hidden");
				$(this).siblings(".collapseAll").removeClass("hidden");

				$(".expand", section).addClass("hidden");
				$(".collapse", section).removeClass("hidden");
			}
			function collapseAll(event)
			{
				var id = $(event.target).attr("query");
				var section = $("#" + id);

				section.addClass("hidden");
				$(".expandable", section).addClass("hidden");
				$(this).addClass("hidden");

				$(this).siblings(".collapse").addClass("hidden");
				$(this).siblings(".expand").removeClass("hidden");
				$(this).siblings(".expandAll").removeClass("hidden");

				$(".expand", section).removeClass("hidden");
				$(".collapse", section).addClass("hidden");
			}


			// connect the correct fuctions
			function sconnect(element) {
				$(".reveal-question", element).click(branchNext);

				$(".expand", element).click(expand);
				$(".expandAll", element).click(expandAll);
				$(".collapse", element).click(collapse);
				$(".collapseAll", element).click(collapseAll);
			}

			// load method for adding connections
			$(document).ready(function() {
				sconnect($(document).children()[0])
			 });

			 $(document).ready(function(){
			 $('.carousel ul').cycle({'prev':'.previous','next':'.next','play':'.play','pause':'.pause'});
			 $(".carousel-hidden").each(function () {
			 $(this).removeClass("carousel-hidden");
			 });
			 });


		</script><!--*********************************************************
    *************************************************************
    REPLACE GOOGLE ANALYTICS SCRIPT BEFORE PUBLISHING TO LIVESITE
    You can find the script in google-analytics.js **************
    *************************************************************
    **********************************************************--><script type="text/javascript">
   
     var _gaq = _gaq || [];
     _gaq.push(['_setAccount', 'UA-19627862-1']);
     _gaq.push(['_trackPageview']);
   
     (function() {
       var ga = document.createElement('script'); ga.type = 'text/javascript'; ga.async = true;
       ga.src = ('https:' == document.location.protocol ? 'https://ssl' : 'http://www') + '.google-analytics.com/ga.js';
       var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(ga, s);
     })();
   
</script></head><body><div class="floatpage"><div id="ucsf"><a href="http://ucsf.edu/"><img src="images/masthead/ucsf.gif" alt="University of California, San Francisco Logo"/></a><p>University of California, San Francisco | <a href="http://www.ucsf.edu/about-ucsf/">About UCSF</a> | <a href="http://www.ucsf.edu/ucsf/search">Search UCSF</a> | <a href="http://www.ucsfhealth.org/">UCSF Medical Center</a></p></div><div id="header"><div style="float:left;"><a href="InSite" style="display:block;"><img src="images/masthead/splash-logo-top.gif" alt="HIV InSite"/></a><h1 class="site-description" style="clear:both; width: 475px;">Comprehensive, up-to-date information on HIV/AIDS treatment and prevention from the University of California San Francisco</h1></div><div class="site-sub-navigation"><a href="InSite">Home</a> | <a href="InSite?page=pb-00-00">Patient/Public</a> | <a href="InSite?page=Audio">Audio</a> | <a href="InSite?page=News">News</a> | <a href="InSite?page=Links">Links</a></div><div class="sitesearch"><form action="search" method="get" id="search"><input type="hidden" name="page" value="sr-00-00"/><input type="hidden" name="post" value="1"/><label for="SearchEntry">Search</label><input type="text" size="28" name="SearchEntry" id="SearchEntry" aria-label="Search"/><input type="submit" id="I1" value="Search" style="margin-left: 5px;"/></form></div><div id="site-navigation"><ul><li class="site-navigation"><a href="InSite?page=KB">Knowledge Base</a></li><li class="site-navigation"><a href="InSite?page=Treatment">Treatment</a></li><li class="site-navigation"><a href="InSite?page=Prevention">Prevention</a></li><li class="site-navigation"><a href="InSite?page=Policy">Policy Analysis</a></li><li class="site-navigation"><a href="InSite?page=cr-00-00">Global Response</a></li></ul></div></div><div id="content-target"><div><table border="0" cellpadding="0" cellspacing="0" width="100%"><tbody><tr><td align="right"><font face="Arial, Helvetica" size="-2"><a href="http://hivinsite.ucsf.edu/InSite">Home</a> &gt; <a href="http://hivinsite.ucsf.edu/InSite?page=Treatment">Treatment</a> &gt; <a href="InSite?page=ar-00-02">Interactions</a></font></td></tr><tr><td><img alt="" src="images/transparent.gif" border="0" height="10" width="1"/></td></tr></tbody></table><div class="pgtitle">Database of Antiretroviral Drug Interactions</div><img alt="" src="images/greyline.gif"/><br/><p style="margin-top:0;padding-top:0;" class="kbrsec1">All Interactions with Tenofovir disoproxil fumarate (Viread)</p><table class="datatable" width="100%"><thead><tr class="header" bgcolor="#b2c3d3"><th>Coadministered Drug</th><th>Dose of Drug</th><th>Dose of Tenofovir disoproxil fumarate</th><th>Effect on Drug Levels</th><th>Effect on Tenofovir disoproxil fumarate Levels</th><th>Potential Clinical Effects</th><th>Mechanism of Interaction</th><th>Management</th></tr></thead><tr><td valign="top" width="10%">Abacavir<sup><a href="#135">135</a></sup><div>(ABC)(Ziagen)</div></td><td valign="top">300 mg BID</td><td valign="top">300 mg QD x 13 days</td><td valign="top">No significant change</td><td valign="top">No significant change</td><td valign="top">-</td><td valign="top">-</td><td valign="top"><p>No dose adjustment necessary</p><p class="warn"><b/></p></td></tr><tr bgcolor="#eeeeee"><td valign="top" width="10%">Adefovir<sup><a href="#235">235</a></sup><div>(Hepsera)</div></td><td valign="top">10 mg QD</td><td valign="top">300 mg QD x 1 dose</td><td valign="top">-</td><td valign="top">No significant change</td><td valign="top">-</td><td valign="top">-</td><td valign="top"><p>No dose adjustment necessary</p><p class="warn"><b/></p></td></tr><tr><td valign="top" width="10%">Atazanavir<sup><a href="#155">155</a></sup><div>(ATV)(Reyataz)</div></td><td valign="top">300 mg QD with 100 mg ritonavir QD x 10 d</td><td valign="top">300 mg QD x 10 d, separated 12 hours away from atazanavir/ritonavir</td><td valign="top">Atazanavir Cmin: decreased 20%</td><td valign="top">Tenofovir AUC: increased 37%; Cmax: increased 34%; Cmin: increased 29%</td><td valign="top">Increased tenofovir effects</td><td valign="top">-</td><td valign="top"><p>Coadminister atazanavir/ritonavir together with tenofovir</p><p class="warn"><b/></p></td></tr><tr bgcolor="#eeeeee"><td valign="top" width="10%">Atazanavir<sup><a href="#148">148</a></sup><div>(ATV)(Reyataz)</div></td><td valign="top">300 mg QD with ritonavir 100 mg QD</td><td valign="top">300 mg QD</td><td valign="top">Atazanavir AUC: no significant change; Cmax: no significant change; Cmin: decreased 21% (compared to atazanavir 300 QD with ritonavir 100 mg QD)Ritonavir AUC: increased 20%; Cmax: no signficant change; Cmin: no significant change</td><td valign="top">-</td><td valign="top">-</td><td valign="top">Unknown</td><td valign="top"><p>No dose adjustment necessary</p><p class="warn"><b/></p></td></tr><tr><td valign="top" width="10%">Atazanavir<sup><a href="#8">8</a>, <a href="#9">9</a>, <a href="#10">10</a></sup><div>(ATV)(Reyataz)</div></td><td valign="top">300 mg QD with ritonavir 100 mg QD on days 1-42</td><td valign="top">300 mg QD on days 15-42</td><td valign="top">Atazanavir Cmax: decreased 28%; AUC: decreased 25%; Cmin: decreased 26%; Ritonavir Cmax: decreased 28%; AUC: decreased 25%; Cmin: no significant change</td><td valign="top">Not studied</td><td valign="top">Decreeased atazanavir effects; possibly increased tenofovir effects</td><td valign="top">-</td><td valign="top"><p>Do not coadminister with unboosted atazanavir (400 mg); Administer 300 mg atazanavir with 100 mg ritonavir when used as part of a tenofovir containing regimen</p><p class="warn"><b/></p></td></tr><tr class="header" bgcolor="#b2c3d3"><th>Coadministered Drug</th><th>Dose of Drug</th><th>Dose of Tenofovir disoproxil fumarate</th><th>Effect on Drug Levels</th><th>Effect on Tenofovir disoproxil fumarate Levels</th><th>Potential Clinical Effects</th><th>Mechanism of Interaction</th><th>Management</th></tr><tr bgcolor="#eeeeee"><td valign="top" width="10%">Atazanavir<sup><a href="#155">155</a></sup><div>(ATV)(Reyataz)</div></td><td valign="top">400 mg QD with 100 mg ritonavir QD x 10 d</td><td valign="top">300 mg QD x 10 d</td><td valign="top">Atazanavir AUC: increased 38%; Cmax: increased 31%; Cmin: increased 33%</td><td valign="top">Tenofovir AUC: increased 55%; Cmax: increased 39%; Cmin: increased 70%</td><td valign="top">Increased atazanavir and tenofovir effects</td><td valign="top">-</td><td valign="top"><p>Do not coadminister</p><p class="warn"><b/></p></td></tr><tr><td valign="top" width="10%">Atazanavir<sup><a href="#9">9</a>, <a href="#123">123</a>, <a href="#124">124</a>, </sup><div>(ATV)(Reyataz)</div></td><td valign="top">400 mg QD with a light meal</td><td valign="top">300 mg QD with a light meal</td><td valign="top">Atazanavir AUC: decreased 26%; Cmax: decreased 24%; Cmin: decreased 40%</td><td valign="top">Tenofovir AUC: increased 25%; Cmax: no significant change</td><td valign="top">Decreased atazanavir effects; increased tenofovir effects</td><td valign="top">Unknown</td><td valign="top"><p>Do not coadminister with unboosted atazanavir (400 mg); Administer 300 mg atazanavir with 100 mg ritonavir when used as part of a tenofovir containing regimen</p><p class="warn"><b/></p></td></tr><tr bgcolor="#eeeeee"><td valign="top" width="10%">Boceprevir<sup><a href="#569">569</a></sup><div>(Victrelis)</div></td><td valign="top">800 mg TID x 7 days</td><td valign="top">300 mg QD x 7 days</td><td valign="top">No significant effect</td><td valign="top">Tenofovir Cmax: increased 32%</td><td valign="top">-</td><td valign="top">-</td><td valign="top"><p>No dose adjustment necessary</p><p class="warn"><b/></p></td></tr><tr><td valign="top" width="10%">Buprenorphine<sup><a href="#443">443</a></sup><div>(Suboxone)(Buprenex)</div></td><td valign="top">16 mg QD</td><td valign="top">300 mg QD</td><td valign="top">No significant change</td><td valign="top">-</td><td valign="top">-</td><td valign="top">-</td><td valign="top"><p>No dose adjustment necessary</p><p class="warn"><b/></p></td></tr><tr bgcolor="#eeeeee"><td valign="top" width="10%">Daclatasvir<sup><a href="#747">747</a></sup><div>(Daklinza)</div></td><td valign="top">60 mg daily</td><td valign="top">300 mg daily</td><td valign="top">Daclatasvir AUC increased 10%; Cmin increased 15%</td><td valign="top">-</td><td valign="top">-</td><td valign="top">-</td><td valign="top"><p> No dose adjustment necessary</p><p class="warn"><b/></p></td></tr><tr><td valign="top" width="10%">Darunavir<sup><a href="#161">161</a></sup><div>(DRV)(Prezista)</div></td><td valign="top">300 mg BID with ritonavir 100 mg BID</td><td valign="top">300 mg QD</td><td valign="top">Darunavir AUC: increased 21%; Cmax: increased 16%; Cmin: increased 24%</td><td valign="top">Tenofovir AUC: increased 22%; Cmax: increased 24%; Cmin: increased 37%</td><td valign="top">Possibly increased darunavir effects; possibly increased tenofovir effects</td><td valign="top">-</td><td valign="top"><p>No dose adjustment necessary</p><p class="warn"><b/></p></td></tr><tr class="header" bgcolor="#b2c3d3"><th>Coadministered Drug</th><th>Dose of Drug</th><th>Dose of Tenofovir disoproxil fumarate</th><th>Effect on Drug Levels</th><th>Effect on Tenofovir disoproxil fumarate Levels</th><th>Potential Clinical Effects</th><th>Mechanism of Interaction</th><th>Management</th></tr><tr bgcolor="#eeeeee"><td valign="top" width="10%">Didanosine<sup><a href="#143">143</a></sup><div>(ddI)(Videx)</div></td><td valign="top">-</td><td valign="top">-</td><td valign="top">-</td><td valign="top">-</td><td valign="top">Potential early virologic failure</td><td valign="top">-</td><td valign="top"><p>Use caution when coadministering tenofovir, didanosine and either efavirenz or nevirapine in treatment-naive patients</p><p class="warn"><b/></p></td></tr><tr><td valign="top" width="10%">Didanosine<sup><a href="#96">96</a></sup><div>(ddI)(Videx)</div></td><td valign="top">250 mg or 400 mg (buffered formulation) QD x 7 days</td><td valign="top">300 mg QD</td><td valign="top">Didanosine AUC: increased 44%; Cmax: increased 28%</td><td valign="top">No significant change</td><td valign="top">Increased didanosine effects</td><td valign="top">Possible shared elimination pathway</td><td valign="top"><p>Reduce didanosine dose to 250 mg QD when used with tenofovir</p><p class="warn"><b/></p></td></tr><tr bgcolor="#eeeeee"><td valign="top" width="10%">Didanosine<sup><a href="#103">103</a></sup><div>(ddI)(Videx)</div></td><td valign="top">250 mg QD (enteric coated) x 1 (given with food, without food and staggered by 2 hours)</td><td valign="top">300 mg QD x 9 days</td><td valign="top">Didanosine AUC: no significant change (fed); Cmax: no significant change; Didanosine AUC: no significant change (staggered); Cmax: no significant change (staggered); Didanosine AUC: no significant change (fed); Cmax: decreased 29% (fed)All values compared to 400 mg QD (enteric coated) reference dose.</td><td valign="top">No significant change</td><td valign="top">-</td><td valign="top">Possible shared elimination pathway</td><td valign="top"><p>Reduce didanosine dose to 250 mg QD when used with tenofovir</p><p class="warn"><b/></p></td></tr><tr><td valign="top" width="10%">Didanosine<sup><a href="#97">97</a>, <a href="#96">96</a></sup><div>(ddI)(Videx)</div></td><td valign="top">400 mg (buffered formulation) QD x 7 days</td><td valign="top">300 mg QD x 7 days</td><td valign="top">Didanosine AUC: increased 44%; Cmax: increased 28%</td><td valign="top">No significant change</td><td valign="top">Increased didanosine effects</td><td valign="top">Possible shared elimination pathway</td><td valign="top"><p>Reduce didanosine dose to 250 mg QD when used with tenofovir</p><p class="warn"><b/></p></td></tr><tr bgcolor="#eeeeee"><td valign="top" width="10%">Didanosine<sup><a href="#96">96</a>, <a href="#102">102</a></sup><div>(ddI)(Videx)</div></td><td valign="top">400 mg (enteric coated capsule) x 1 dose</td><td valign="top">300 mg QD</td><td valign="top">Didanosine AUC: increased 48% (fasted); Cmax: increased 48% (fasted)Didanosine AUC: increased 60% (fed); Cmax: increased 64% (fed)</td><td valign="top">No significant change</td><td valign="top">Increased didanosine effects</td><td valign="top">Possible shared elimination pathway</td><td valign="top"><p>Reduce didanosine dose to 250 mg QD when used with tenofovir</p><p class="warn"><b/></p></td></tr><tr><td valign="top" width="10%">Didanosine<sup><a href="#96">96</a></sup><div>(ddI)(Videx)</div></td><td valign="top">400 mg QD (enteric coated) x 7 days (given with food)</td><td valign="top">300 mg QD</td><td valign="top">-</td><td valign="top">-</td><td valign="top">Increased didanosine effects</td><td valign="top">Possible shared elimination pathway</td><td valign="top"><p>Reduce didanosine dose to 250 mg QD when used with tenofovir</p><p class="warn"><b/></p></td></tr><tr class="header" bgcolor="#b2c3d3"><th>Coadministered Drug</th><th>Dose of Drug</th><th>Dose of Tenofovir disoproxil fumarate</th><th>Effect on Drug Levels</th><th>Effect on Tenofovir disoproxil fumarate Levels</th><th>Potential Clinical Effects</th><th>Mechanism of Interaction</th><th>Management</th></tr><tr bgcolor="#eeeeee"><td valign="top" width="10%">Didanosine<sup><a href="#96">96</a></sup><div>(ddI)(Videx)</div></td><td valign="top">400 mg QD (enteric coated) x 7 days (given without food)</td><td valign="top">300 mg QD</td><td valign="top">Didanosine AUC: increased 48%; Cmax: increased 28%</td><td valign="top">Not studied</td><td valign="top">Increased didanosine effects</td><td valign="top">Possible shared elimination pathway</td><td valign="top"><p>Reduce didanosine dose to 250 mg QD when used with tenofovir</p><p class="warn"><b/></p></td></tr><tr><td valign="top" width="10%">Dolutegravir<sup><a href="#641">641</a></sup><div>(Tivicay)</div></td><td valign="top">50 mg QD</td><td valign="top">300 mg QD</td><td valign="top">No significant change</td><td valign="top"> TDF AUC: increased 12%; Cmin: increased 19%</td><td valign="top">-</td><td valign="top">-</td><td valign="top"><p>No dose adjustment necessary</p><p class="warn"><b/></p></td></tr><tr bgcolor="#eeeeee"><td valign="top" width="10%">Efavirenz<sup><a href="#143">143</a></sup><div>(EFV)(Sustiva)</div></td><td valign="top">-</td><td valign="top">-</td><td valign="top">- </td><td valign="top">- </td><td valign="top">Potential early virologic failure</td><td valign="top">- </td><td valign="top"><p>Use caution when coadministering tenofovir, didanosine and either efavirenz or nevirapine in treatment-naive patients</p><p class="warn"><b> </b></p></td></tr><tr><td valign="top" width="10%">Efavirenz<sup><a href="#96">96</a>, <a href="#98">98</a></sup><div>(EFV)(Sustiva)</div></td><td valign="top">600 mg QD x 14 days</td><td valign="top">300 mg QD x 7 days</td><td valign="top">No significant change</td><td valign="top">No significant change</td><td valign="top">-</td><td valign="top">-</td><td valign="top"><p>No dose adjustment necessary</p><p class="warn"><b/></p></td></tr><tr bgcolor="#eeeeee"><td valign="top" width="10%">Emtricitabine<sup><a href="#125">125</a>, <a href="#126">126</a></sup><div>(FTC)(Emtriva)</div></td><td valign="top">200 mg QD x 7 days</td><td valign="top">300 mg QD x 7 days</td><td valign="top">No significant change</td><td valign="top">No significant change</td><td valign="top">-</td><td valign="top">-</td><td valign="top"><p>No dose adjustment necessary</p><p class="warn"><b/></p></td></tr><tr><td valign="top" width="10%">Emtricitabine<sup><a href="#96">96</a></sup><div>(FTC)(Emtriva)</div></td><td valign="top">200 mg QD x 7 days</td><td valign="top">300 mg QD</td><td valign="top">No significant change</td><td valign="top">No significant change</td><td valign="top">-</td><td valign="top">-</td><td valign="top"><p>No dose adjustment necessary</p><p class="warn"><b/></p></td></tr><tr class="header" bgcolor="#b2c3d3"><th>Coadministered Drug</th><th>Dose of Drug</th><th>Dose of Tenofovir disoproxil fumarate</th><th>Effect on Drug Levels</th><th>Effect on Tenofovir disoproxil fumarate Levels</th><th>Potential Clinical Effects</th><th>Mechanism of Interaction</th><th>Management</th></tr><tr bgcolor="#eeeeee"><td valign="top" width="10%">Entecavir<sup><a href="#391">391</a></sup><div>(Baraclude)</div></td><td valign="top">-</td><td valign="top">-</td><td valign="top">No significant change</td><td valign="top">No significant change</td><td valign="top">-</td><td valign="top">-</td><td valign="top"><p>No dose adjustment necessary</p><p class="warn"><b/></p></td></tr><tr><td valign="top" width="10%">Ethinyl estradiol/norethindrone acetate<sup><a href="#367">367</a></sup><div>(others)(Ortho-Novum)</div></td><td valign="top">1 tab QD</td><td valign="top">300 mg QD</td><td valign="top">No significant change</td><td valign="top">No significant change</td><td valign="top">-</td><td valign="top">-</td><td valign="top"><p>No dose adjustment necessary</p><p class="warn"><b/></p></td></tr><tr bgcolor="#eeeeee"><td valign="top" width="10%">Ethinyl estradiol/norgestimate<sup><a href="#430">430</a></sup><div>(others)(Ortho Tri-Cyclen, Ortho Tri-Cyclen)</div></td><td valign="top">1 tab QD</td><td valign="top">300 mg QD</td><td valign="top">Ethinyl estradiol: no significant effect; Deacetyl norgestimate: no significant effect</td><td valign="top">- </td><td valign="top">-</td><td valign="top">- </td><td valign="top"><p>No dose adjustment necessary</p><p class="warn"><b> </b></p></td></tr><tr><td valign="top" width="10%">Etravirine<sup><a href="#429">429</a></sup><div>(ETR)(Intelence)</div></td><td valign="top">200 mg BID</td><td valign="top">300 mg QD</td><td valign="top">Etravirine AUC: decreased 19%; Cmin: decreased 18%; Cmax: decreased 19%</td><td valign="top">Tenofovir AUC: increased 15%; Cmin: increased 19%; Cmax: increased 15%</td><td valign="top">- </td><td valign="top">- </td><td valign="top"><p>No dose adjustment necessary</p><p class="warn"><b> </b></p></td></tr><tr bgcolor="#eeeeee"><td valign="top" width="10%">Fosamprenavir<sup><a href="#153">153</a></sup><div>(FPV)(Lexiva)</div></td><td valign="top">1400 mg with 100 mg ritonavir QD x 14 days</td><td valign="top">300 mg QD</td><td valign="top">Amprenavir AUC: no significant change; Cmax: no significant change; Cmin: increased 24%</td><td valign="top">No significant change</td><td valign="top">-</td><td valign="top">-</td><td valign="top"><p>No dose adjustment necessary</p><p class="warn"><b/></p></td></tr><tr><td valign="top" width="10%">Fosamprenavir<sup><a href="#153">153</a></sup><div>(FPV)(Lexiva)</div></td><td valign="top">1400 mg with 200 mg ritonavir QD x 14 days</td><td valign="top">300 mg QD</td><td valign="top">No significant change</td><td valign="top">No significant change</td><td valign="top">-</td><td valign="top">-</td><td valign="top"><p>No dose adjustment necessary</p><p class="warn"><b/></p></td></tr><tr class="header" bgcolor="#b2c3d3"><th>Coadministered Drug</th><th>Dose of Drug</th><th>Dose of Tenofovir disoproxil fumarate</th><th>Effect on Drug Levels</th><th>Effect on Tenofovir disoproxil fumarate Levels</th><th>Potential Clinical Effects</th><th>Mechanism of Interaction</th><th>Management</th></tr><tr bgcolor="#eeeeee"><td valign="top" width="10%">Indinavir<sup><a href="#96">96</a>, <a href="#98">98</a></sup><div>(IDV)(Crixivan)</div></td><td valign="top">800 mg TID x 7 days</td><td valign="top">300 mg QD x 7 days</td><td valign="top">No significant change</td><td valign="top">No significant change</td><td valign="top">-</td><td valign="top">-</td><td valign="top"><p>No dose adjustment necessary</p><p class="warn"><b/></p></td></tr><tr><td valign="top" width="10%">Lamivudine<sup><a href="#96">96</a>, <a href="#97">97</a></sup><div>(3TC)(Epivir)</div></td><td valign="top">150 mg BID x 7 days</td><td valign="top">300 mg QD x 7 days</td><td valign="top">Lamivudine Cmax: decreased 24%</td><td valign="top">No significant change</td><td valign="top">- </td><td valign="top">- </td><td valign="top"><p>No dose adjustment necessary</p><p class="warn"><b> </b></p></td></tr><tr bgcolor="#eeeeee"><td valign="top" width="10%">Ledipasvir/sofosbuvir<sup><a href="#727">727</a>, <a href="#713">713</a></sup><div/></td><td valign="top">Ledipasvir 90 mg with sofosbuvir 400 mg QD</td><td valign="top">300 mg QD</td><td valign="top">-</td><td valign="top"> TDF AUC ↑ 40%-98% when TDF co-administered with rilpivirine and efavirenz.  Further ↑ TDF possible if co-administered with protease inhibitors.</td><td valign="top">-</td><td valign="top">-</td><td valign="top"><p>No dose adjustment necessary, consider renal function and avoid use if CrCl &lt;60 ml/min. Monitor for TDF toxicity</p><p class="warn"><b/></p></td></tr><tr><td valign="top" width="10%">Lopinavir/ritonavir<sup><a href="#96">96</a>, <a href="#98">98</a></sup><div>(LPV/r)(Kaletra)</div></td><td valign="top">400 mg/100 mg BID x 14 days</td><td valign="top">300 mg QD</td><td valign="top">Lopinavir AUC: decreased 15%; Cmax: decreased 15%; Cmin: no significant change; Ritonavir AUC: decreased 24%; Cmax: decreased 28%; Cmin: no significant change</td><td valign="top">Tenofovir AUC: increased 34%; Cmax: increased 31%; Cmin: increased 29%</td><td valign="top">Increased tenofovir effects</td><td valign="top">-</td><td valign="top"><p>No dose adjustment necessary</p><p class="warn"><b/></p></td></tr><tr bgcolor="#eeeeee"><td valign="top" width="10%">Lopinavir/ritonavir<sup><a href="#104">104</a></sup><div>(LPV/r)(Kaletra)</div></td><td valign="top">400/100 mg BID</td><td valign="top">300 mg QD</td><td valign="top">Lopinavir: no significant change. Ritonavir: no significant change</td><td valign="top">Not studied</td><td valign="top">-</td><td valign="top">-</td><td valign="top"><p>No dose adjustment necessary</p><p class="warn"><b/></p></td></tr><tr><td valign="top" width="10%">Lopinavir/ritonavir<sup><a href="#78">78</a>, <a href="#96">96</a></sup><div>(LPV/r)(Kaletra)</div></td><td valign="top">400/100 mg BID</td><td valign="top">300 mg QD</td><td valign="top">No significant change</td><td valign="top">Tenofovir AUC: increased 32%; Cmin: increased 51%; half-life: no significant change</td><td valign="top">Possibly increased tenofovir effects</td><td valign="top">- </td><td valign="top"><p>No dose adjustment necessary</p><p class="warn"><b> </b></p></td></tr><tr class="header" bgcolor="#b2c3d3"><th>Coadministered Drug</th><th>Dose of Drug</th><th>Dose of Tenofovir disoproxil fumarate</th><th>Effect on Drug Levels</th><th>Effect on Tenofovir disoproxil fumarate Levels</th><th>Potential Clinical Effects</th><th>Mechanism of Interaction</th><th>Management</th></tr><tr bgcolor="#eeeeee"><td valign="top" width="10%">Methadone<sup><a href="#185">185</a></sup><div>(Dolophine)</div></td><td valign="top">40-110 mg/day</td><td valign="top">300 mg QD</td><td valign="top">No significant change</td><td valign="top">Not reported</td><td valign="top">-</td><td valign="top">-</td><td valign="top"><p>No dose adjustment necessary</p><p class="warn"><b/></p></td></tr><tr><td valign="top" width="10%">Methadone<sup><a href="#96">96</a>, <a href="#188">188</a></sup><div>(Dolophine)</div></td><td valign="top">stable dose (range 45-130 mg) QD</td><td valign="top">300 mg QD on days 2-15</td><td valign="top">R-methadone: no significant change;S-methadone: no significant change;total methadone: no significant change</td><td valign="top">Not studied</td><td valign="top">-</td><td valign="top">-</td><td valign="top"><p>No dose adjustment necessary</p><p class="warn"><b/></p></td></tr><tr bgcolor="#eeeeee"><td valign="top" width="10%">Nevirapine<sup><a href="#143">143</a></sup><div>(NVP)(Viramune)</div></td><td valign="top">-</td><td valign="top">-</td><td valign="top">-</td><td valign="top">-</td><td valign="top">Potential early virologic failure</td><td valign="top">-</td><td valign="top"><p>Use caution when coadministering tenofovir, didanosine and either efavirenz or nevirapine in treatment naive patients</p><p class="warn"><b/></p></td></tr><tr><td valign="top" width="10%">Probenecid<sup><a href="#96">96</a></sup><div>(Benemid)(Benemid)</div></td><td valign="top">- </td><td valign="top">- </td><td valign="top">No significant change</td><td valign="top">Increased tenofovir levels</td><td valign="top">Increased tenofovir effects</td><td valign="top">Probenecid-induced inhibition of the renal tubular secretion of tenofovir</td><td valign="top"><p>Avoid combination</p><p class="warn"><b> </b></p></td></tr><tr bgcolor="#eeeeee"><td valign="top" width="10%">Raltegravir<sup><a href="#3">3</a></sup><div>(RAL)(Isentress)</div></td><td valign="top">400 mg BID</td><td valign="top">300 mg QD</td><td valign="top">Raltegravir AUC: increased 49%; Cmax: increased 64%</td><td valign="top">-</td><td valign="top">Possibly increased raltegravir effects</td><td valign="top">-</td><td valign="top"><p>No dose adjustment necessary</p><p class="warn"><b/></p></td></tr><tr><td valign="top" width="10%">Ribavirin<sup><a href="#235">235</a></sup><div>(Rebetol, Virazole)</div></td><td valign="top">800 mg QD</td><td valign="top">300 mg QD x 1 dose</td><td valign="top">-</td><td valign="top">No significant change</td><td valign="top">-</td><td valign="top">-</td><td valign="top"><p>No dose adjustment necessary</p><p class="warn"><b/></p></td></tr><tr class="header" bgcolor="#b2c3d3"><th>Coadministered Drug</th><th>Dose of Drug</th><th>Dose of Tenofovir disoproxil fumarate</th><th>Effect on Drug Levels</th><th>Effect on Tenofovir disoproxil fumarate Levels</th><th>Potential Clinical Effects</th><th>Mechanism of Interaction</th><th>Management</th></tr><tr bgcolor="#eeeeee"><td valign="top" width="10%">Rifampin<sup><a href="#348">348</a>, <a href="#349">349</a></sup><div>(Rifampicin)(Rifadin)</div></td><td valign="top">600 mg QD on days 11-21</td><td valign="top">300 mg QD on days 1-20</td><td valign="top">No significant change</td><td valign="top">No significant change</td><td valign="top">-</td><td valign="top">-</td><td valign="top"><p>No dose adjustment necessary</p><p class="warn"><b/></p></td></tr><tr><td valign="top" width="10%">Rilpivirine<sup><a href="#567">567</a></sup><div>(RPV)(Edurant)</div></td><td valign="top">150 mg QD</td><td valign="top">300 mg QD</td><td valign="top">No significant change</td><td valign="top">Tenofovir AUC: increased 23%; Cmin: increased 24%; Cmax: increased 19%</td><td valign="top">Potentially increased tenofovir effects</td><td valign="top">-</td><td valign="top"><p>No dose adjustment necessary</p><p class="warn"><b/></p></td></tr><tr bgcolor="#eeeeee"><td valign="top" width="10%">Saquinavir<sup><a href="#149">149</a></sup><div>(SQV)(Fortovase, Invirase)</div></td><td valign="top">1000 mg (hard gel caps) with ritonavir 100 mg BID on days 1-14</td><td valign="top">300 mg QD on days 3-14</td><td valign="top">Saquinavir AUC: no significant change; Cmax: no significant change; Cmin: no significant changeRitonavir AUC: no significant change; Cmax: no significant change; Cmin: increased 27%</td><td valign="top">Not studied</td><td valign="top">-</td><td valign="top">-</td><td valign="top"><p>No dose adjustment necessary</p><p class="warn"><b/></p></td></tr><tr><td valign="top" width="10%">Saquinavir<sup><a href="#142">142</a></sup><div>(SQV)(Fortovase, Invirase)</div></td><td valign="top">1000 mg BID with 100 mg ritonavir on days 1-14</td><td valign="top">300 mg QD on days 2-14</td><td valign="top">No significant change either for saquinavir or ritonavir</td><td valign="top">No significant change</td><td valign="top">-</td><td valign="top">-</td><td valign="top"><p>No dose adjustment necessary</p><p class="warn"><b/></p></td></tr><tr bgcolor="#eeeeee"><td valign="top" width="10%">Saquinavir<sup><a href="#145">145</a></sup><div>(SQV)(Fortovase, Invirase)</div></td><td valign="top">1000 mg saquinavir BID with 100 mg ritonavir BID</td><td valign="top">300 mg QD</td><td valign="top">Saquinavir AUC: increased 29%; Cmax: increased 22%; Cmin: incresed 47%</td><td valign="top">Tenofovir Cmin: increased 23%</td><td valign="top">-</td><td valign="top">-</td><td valign="top"><p>No dose adjustment necessary</p><p class="warn"><b/></p></td></tr><tr><td valign="top" width="10%">Simeprevir<sup><a href="#679">679</a></sup><div>(Olysio)</div></td><td valign="top">150 mg QD x 7 days</td><td valign="top">300 mg QD x 7 days</td><td valign="top">Simeprevir AUC: decreased 24%; Cmax: decreased 15%</td><td valign="top">Tenofovir AUC: increased 18%; Cmax: increased 19%; Cmin: increased 24% </td><td valign="top">-</td><td valign="top">-</td><td valign="top"><p>No dose adjustment necessary</p><p class="warn"><b/></p></td></tr><tr class="header" bgcolor="#b2c3d3"><th>Coadministered Drug</th><th>Dose of Drug</th><th>Dose of Tenofovir disoproxil fumarate</th><th>Effect on Drug Levels</th><th>Effect on Tenofovir disoproxil fumarate Levels</th><th>Potential Clinical Effects</th><th>Mechanism of Interaction</th><th>Management</th></tr><tr bgcolor="#eeeeee"><td valign="top" width="10%">Sofosbuvir<sup><a href="#659">659</a></sup><div>(Sovaldi)</div></td><td valign="top">400 mg x 1</td><td valign="top">300 mg QD</td><td valign="top">Sofosbuvir Cmax increased 25%</td><td valign="top">-</td><td valign="top">-</td><td valign="top">-</td><td valign="top"><p>No dose adjustment necessary</p><p class="warn"><b/></p></td></tr><tr><td valign="top" width="10%">Stavudine<sup><a href="#12">12</a></sup><div>(d4T)(Zerit)</div></td><td valign="top">100 mg extended release x 1 dose</td><td valign="top">300 mg QD x 7 days</td><td valign="top">No significant change</td><td valign="top">Not studied</td><td valign="top">-</td><td valign="top">-</td><td valign="top"><p>No dose adjustment necessary</p><p class="warn"><b/></p></td></tr><tr bgcolor="#eeeeee"><td valign="top" width="10%">Stavudine<sup><a href="#136">136</a></sup><div>(d4T)(Zerit)</div></td><td valign="top">100 mg XR QD on days 1 and 9</td><td valign="top">300 mg QD on days 2-9</td><td valign="top">-</td><td valign="top">No significant change</td><td valign="top">-</td><td valign="top">-</td><td valign="top"><p>No dose adjustment necessary</p><p class="warn"><b/></p></td></tr><tr><td valign="top" width="10%">Telaprevir<sup><a href="#571">571</a></sup><div>(Incivek)</div></td><td valign="top">1125 mg Q8H x 7 days</td><td valign="top">300 mg QD administered with 600 mg efavirenz QD x 7 days</td><td valign="top">Telaprevir AUC: decreased 18%; Cmin: decreased 25%</td><td valign="top">Tenofovir Cmin: increased 17%; Cmax: increased 22%</td><td valign="top">Possibly increased tenofovir effects</td><td valign="top">-</td><td valign="top"><p>No dose adjustment necessary</p><p class="warn"><b/></p></td></tr><tr bgcolor="#eeeeee"><td valign="top" width="10%">Telaprevir<sup><a href="#571">571</a></sup><div>(Incivek)</div></td><td valign="top">1500 mg Q12H x 7 days</td><td valign="top">300 mg QD administered with efavirenz 600 mg QD x 7 days</td><td valign="top">Telaprevir AUC: decreased 20%; Cmin: decreased 48%</td><td valign="top">Tenofovir Cmax: increased 24%</td><td valign="top">Potentially decreased telaprevir effects</td><td valign="top">-</td><td valign="top"><p>Dose adjust telaprevir to 1125 mg Q8H when used with efavirenz.</p><p class="warn"><b/></p></td></tr><tr><td valign="top" width="10%">Telaprevir<sup><a href="#571">571</a></sup><div>(Incivek)</div></td><td valign="top">750 mg Q8H x 7 days</td><td valign="top">300 mg QD x 7 days</td><td valign="top">No significant effect</td><td valign="top">Tenofovir AUC: increased 30%; Cmin: increased 41%; Cmax: increased 30%</td><td valign="top">Possibly increased tenofovir effects</td><td valign="top">-</td><td valign="top"><p>Dose adjustment not established</p><p class="warn"><b/></p></td></tr><tr bgcolor="#eeeeee"><td valign="top" width="10%">Tipranavir<sup><a href="#154">154</a></sup><div>(TPV)(Aptivus)</div></td><td valign="top">500 mg BID with 100 mg ritonavir BID</td><td valign="top">300 mg x 1 dose</td><td valign="top">Tipranavir Cmin: decreased 21%</td><td valign="top">Tenofovir Cmax: decreased 23%</td><td valign="top">-</td><td valign="top">-</td><td valign="top"><p>No dose adjustment necessary</p><p class="warn"><b/></p></td></tr><tr><td valign="top" width="10%">Tipranavir<sup><a href="#154">154</a></sup><div>(TPV)(Aptivus)</div></td><td valign="top">750 mg BID with 200 mg ritonavir BID x 23 doses</td><td valign="top">300 mg x 1 dose</td><td valign="top">No significant change</td><td valign="top">Tenofovir Cmax: decreased 38%</td><td valign="top">-</td><td valign="top">-</td><td valign="top"><p>No dose adjustment necessary</p><p class="warn"><b/></p></td></tr><tr bgcolor="#bbbbbb"><td class="cellleft" colspan="8">"-" indicates that there are no data available
                
            </td></tr></table><table cellspacing="2" cellpadding="0" border="0"><tr><td valign="top" class="cellrightblue"><a name="3"> </a>3:</td><td class="cellleft">Isentress [package insert]. Whitehouse Station, NJ: Merck &amp; Co., Inc.; October 2007.</td></tr><tr><td valign="top" class="cellrightblue"><a name="8"> </a>8:</td><td class="cellleft">Taburet AM, Piketty C, Gerard L, et al. Pharmacokinetic parameters of atazanavir/ritonavir when combined to tenofovir in HIV infected patients with multiple treatment failures: a substudy of Puzzle2-ANRS 107 trial [abstract #537]. 10th Conference on Retroviruses and Opportunistic Infections; 2003 February 10-14; Boston, Massachusetts.</td></tr><tr><td valign="top" class="cellrightblue"><a name="9"> </a>9:</td><td class="cellleft">Data on file. Bristol-Myers Squibb Company. Princeton, NJ.</td></tr><tr><td valign="top" class="cellrightblue"><a name="10"> </a>10:</td><td class="cellleft">Taburet A-M, Piketty C, Chazallon C, et al. Interactions between atazanavir-ritonavir and tenofovir in heavily pretreated human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 2004; 48: 2091-96.</td></tr><tr><td valign="top" class="cellrightblue"><a name="12"> </a>12:</td><td class="cellleft">Kaul S, Bassi K, Damle B, et al. Lack of interaction between stavudine extended-release formulation and tenofovir disoproxil fumarate [abstract #534]. 10th Conference on Retroviruses and Opportunistic Infections; 2003 February 10-14; Boston, Massachusetts.</td></tr><tr><td valign="top" class="cellrightblue"><a name="78"> </a>78:</td><td class="cellleft">Kaletra [package insert]. North Chicago, IL: Abbott Laboratories; Oct 2005.</td></tr><tr><td valign="top" class="cellrightblue"><a name="96"> </a>96:</td><td class="cellleft">Viread [package insert]. Foster City, CA: Gilead Sciences, Inc.; March 2006.</td></tr><tr><td valign="top" class="cellrightblue"><a name="97"> </a>97:</td><td class="cellleft">Kearney B, Flaherty J, Sayre J, et al. A multiple-dose, randomized, crossover, drug interaction study between tenofovir DF and lamivudine or didanosine [abstract #337]. 1st International AIDS Society Conference on HIV Treatment and Pathogenesis; 2001 July 8-11th; Buenos Aires, Argentina.</td></tr><tr><td valign="top" class="cellrightblue"><a name="98"> </a>98:</td><td class="cellleft">Flaherty J, Kearney B, Wolf J, et al. A multiple-dose, randomized, crossover, drug interaction study between tenofovir DF and efavirenz, indinavir or lopinavir/ritonavir [abstract #336]. 1st International AIDS Society Conference on HIV Treatment and Pathogenesis; 2001 July 8-11th; Buenos Aires, Argentina.</td></tr><tr><td valign="top" class="cellrightblue"><a name="102"> </a>102:</td><td class="cellleft">Kearney B, Damle B, Plummer A, et al. Pharmacokinetics evaluation of tenofovir DF and enteric-coated didanosine. Sixth International Congress on Drug Therapy in HIV Infection; 2002 November 17-21; Glasgow, United Kingdom.</td></tr><tr><td valign="top" class="cellrightblue"><a name="103"> </a>103:</td><td class="cellleft">Kearney BP, Isaacson E, Sayre J, et al. Didanosine and tenofovir DF drug-drug interaction: assessment of didanosine dose reduction [abstract #533]. 10th Conference on Retroviruses and Opportunistic Infections; 2003 February 10-14; Boston, Massachusetts.</td></tr><tr><td valign="top" class="cellrightblue"><a name="104"> </a>104:</td><td class="cellleft">Poirier J, Meynard J, Guiard-Schmid J, et al. Lack of alteration of lopinavir and ritonavir trough plasma concentrations in HIV-experienced patients treated with Kaletra and tenofovir DF. [abstract #H-1715]. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2002 September 27-30; Chicago, Illinois.</td></tr><tr><td valign="top" class="cellrightblue"><a name="123"> </a>123:</td><td class="cellleft">Dear Health Care Provider letter. Bristol-Myers Squibb Co., Aug 8, 2003.</td></tr><tr><td valign="top" class="cellrightblue"><a name="124"> </a>124:</td><td class="cellleft">Kaul S, Bassi K, Damle B, et al. Pharmacokinetic evaluation of the combination of atazanavir (ATV), enteric coated didanosine (ddI-EC), and tenofovir disoproxil fumarate (TDF) for a once-daily antiretroviral regimen [abstract #A-1616]. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2003 September 14-17; Chicago, Illinois.</td></tr><tr><td valign="top" class="cellrightblue"><a name="125"> </a>125:</td><td class="cellleft">Emtriva [package insert]. Foster City, CA: Gilead Sciences, Inc.; Sept 2005.</td></tr><tr><td valign="top" class="cellrightblue"><a name="126"> </a>126:</td><td class="cellleft">Blum MR, Begley J, Zong J, et al. Lack of a pharmacokinetic interaction between emtricitabine and tenofovir DF when coadministered to steady state in healthy volunteers [abstract #A-1621]. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2003 September 14-17; Chicago, Illinois.</td></tr><tr><td valign="top" class="cellrightblue"><a name="135"> </a>135:</td><td class="cellleft">Kearney BP, Isaacson E, Sayre J, et al. The pharmacokinetics of abacavir, a purine nucleoside analog, are not affected by tenofovir DF [abstract #A-1615]. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2003 September 14-17; Chicago, Illinois.</td></tr><tr><td valign="top" class="cellrightblue"><a name="136"> </a>136:</td><td class="cellleft">Kaul S, Bassi K, Damle B, et al. Stavudine extended release formulation and tenofovir disoproxil fumarate: lack of a pharmacokinetic drug interaction [abstract #602]. 11th Conference on Retroviruses and Opportunistic Infections; 2004 Feb 8-11; San Francisco, California.</td></tr><tr><td valign="top" class="cellrightblue"><a name="142"> </a>142:</td><td class="cellleft">Boffito M, Back D, Stainsby-Tron M, et al. Tenofovir does not alter the pharmacokinetics os saquinavir hard gel capsule/ritonavir; data from HIV patients [abstract TuPeB4610]. XV International AIDS Conference; 2004 July 11-16; Bangkok, Thailand.</td></tr><tr><td valign="top" class="cellrightblue"><a name="143"> </a>143:</td><td class="cellleft">Bristol-Myers Squibb Company. Potential early virologic failure associated with the combination antiretroviral regimen of tenofovir disoproxil fumarate, didanosine and either efavirenz or nevirapine in HIV treatment-naive patients with high baseline viral loads. Dear Health Care Provider letter. November 2004.</td></tr><tr><td valign="top" class="cellrightblue"><a name="145"> </a>145:</td><td class="cellleft">Zong J, Chittick G, Blum MR, et al. Pharmacokinetic assessment of tenofovir DF and ritonavir-boosted saquinavir in healthy subjexts [abstract A-444]. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2004 Oct 30-Nov 2; Washington, D.C.</td></tr><tr><td valign="top" class="cellrightblue"><a name="148"> </a>148:</td><td class="cellleft">von Hentig N, Haberl A, Lutz T, et al. Concomitant intake of tenofovir disoproxil fumarate does not impair the plasma exposure of ritonavir-boosted atazanavir in HIV-1 infected adults [abstract PI-40]. American Society for Clinical Pharmacology and Therapeutics; 2005 March 2-6; Orlando, Florida.</td></tr><tr><td valign="top" class="cellrightblue"><a name="149"> </a>149:</td><td class="cellleft">Boffito M, Back D, Stainsby-Tron M, et al. Pharmacokinetics of saquinavir hard gel/ritonavir (1000/100 mg twice daily) when administered with tenofovir diproxil fumarate in HIV-1 infected subjects. Br J Clin Pharmacol 2004; 59: 38-42.</td></tr><tr><td valign="top" class="cellrightblue"><a name="153"> </a>153:</td><td class="cellleft">Kurowski M, Walli R, Breske A, et al. Coadministration of tenofovir 300 mg QD with fosamprenavir/ritonavir 1400/100 mg QD or 1400/200 mg QD doses not affect amprenavir pharmacokinetics (COL 20081)[abstact #10]. 6th International Workshop on Clinical Pharmacology of HIV Therapy; 2005 April 28-30; Quebec City, Quebec, Canada.</td></tr><tr><td valign="top" class="cellrightblue"><a name="154"> </a>154:</td><td class="cellleft">Aptivus [package insert]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc.; Nov 2005.</td></tr><tr><td valign="top" class="cellrightblue"><a name="155"> </a>155:</td><td class="cellleft">Agarwala S, Eley T, Villegas C, et al. Pharmacokinetic interaction between tenofovir and atazanavir coadministered with ritonavir in healthy subjects [abst. 16]. 6th International Workshop on Clinical Pharmacology of HIV Therapy; 2005 April 28-30; Quebec City, Canada.</td></tr><tr><td valign="top" class="cellrightblue"><a name="161"> </a>161:</td><td class="cellleft">Prezista [package insert]. Raritan, NJ: Tibotec Therapeutics Inc.; April 2010.</td></tr><tr><td valign="top" class="cellrightblue"><a name="185"> </a>185:</td><td class="cellleft">Smith P, Kearney B, Cloen D, et al. Tenofovir DF does not affect the pharmokinetics or pharmacodynamics of methadone [abst 869]. 2nd International Conference on HIV Pathogenesis and Treatment; 2003 July 13-16; Paris, France.</td></tr><tr><td valign="top" class="cellrightblue"><a name="188"> </a>188:</td><td class="cellleft">Smith PF, Kearney BP, Liaw S, et al. Effect of tenofovir disoproxil fumarate on the pharmacokinetics and pharmacodynamics of total, R- and S-methadone. Pharmacother 2004: 24: 970-77.</td></tr><tr><td valign="top" class="cellrightblue"><a name="235"> </a>235:</td><td class="cellleft">Kearney BP, Benhamou Y, Flaherty J, et al. Tenofovir pharmacokinetics in hepatic impairment and drug interaction potential with agents used to treat viral hepatitis [abstract #600]. 11th Conference on Retroviruses and Opportunistic Infections; 2004 Feb 8-11; San Francisco, California.</td></tr><tr><td valign="top" class="cellrightblue"><a name="348"> </a>348:</td><td class="cellleft">Burger DM, Droste JAH, Kearney BP, et al. Lack of clinically relevant drug-drug interaction between tenofovir DF and rifampin in healthy volunteers [abstract TuPeB4623]. XV International AIDS Conference; 2004 July 11-16; Bangkok, Thailand.</td></tr><tr><td valign="top" class="cellrightblue"><a name="349"> </a>349:</td><td class="cellleft">Droste JA, Verweij-van Wissen CP, Kearney BP, et al. Pharmacokinetic study of tenofovir disoproxil fumarate combined with rifampin in healthy volunteers. Antimicrob Agents Chemother 2005; 49: 680-4.</td></tr><tr><td valign="top" class="cellrightblue"><a name="367"> </a>367:</td><td class="cellleft">Kearney BP, Isaacson E, Sayre J, et al. Tenofovir DF and oral contraceptives: lack of a pharmacokinetic drug interaction [abstract #A-1618]. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2003 September 14-17; Chicago, Illinois.</td></tr><tr><td valign="top" class="cellrightblue"><a name="391"> </a>391:</td><td class="cellleft">Baraclude [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; 2005.</td></tr><tr><td valign="top" class="cellrightblue"><a name="429"> </a>429:</td><td class="cellleft">Scholler-Gyure M, Debroye C, Woodfall B, et al . Pharmacokinetic evaluation of the interaction between TMC125 and tenofovir disoproxil fumarate [poster A-371]. Poster presentation at the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 27-&#147;30, 2006.</td></tr><tr><td valign="top" class="cellrightblue"><a name="430"> </a>430:</td><td class="cellleft">Kearney BP and Mathias A. Lack of effect of tenofovir disoproxil fumarate on pharmacokinetics of hormonal contraceptives. Pharmacother 2009; 29: 924-29.</td></tr><tr><td valign="top" class="cellrightblue"><a name="443"> </a>443:</td><td class="cellleft">Gruber VA, Baker J, Moody DE, et al. Interactions between buprenorphine and antiretrovirals: nucleos(t)ide reverse transcriptase inhibitors didanosine, lamivudine and tenofovir [abstract A1-1306]. 49th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2009 September 12-15; San Francisco, California.</td></tr><tr><td valign="top" class="cellrightblue"><a name="567"> </a>567:</td><td class="cellleft">Edurant [package insert]. Raritan, NJ: Tibotec Therapeutics Inc.; May 2011.</td></tr><tr><td valign="top" class="cellrightblue"><a name="569"> </a>569:</td><td class="cellleft">Victrelis [package insert]. Whitehouse Station, NJ: Schering Corporation; May 2011.</td></tr><tr><td valign="top" class="cellrightblue"><a name="571"> </a>571:</td><td class="cellleft">Incivek [package insert]. Cambridge, MA: Vertex Pharmaceuticals Inc; May 2011.</td></tr><tr><td valign="top" class="cellrightblue"><a name="641"> </a>641:</td><td class="cellleft">Tivicay [package insert]. Research Triangle Park, NC: Viiv Healthcare; Sept 2013.</td></tr><tr><td valign="top" class="cellrightblue"><a name="659"> </a>659:</td><td class="cellleft">Sovaldi [package insert]. Foster City, CA: Gilead Sciences; 2013.</td></tr><tr><td valign="top" class="cellrightblue"><a name="679"> </a>679:</td><td class="cellleft">Olysio [package insert]. Titusville, NJ: Janssen Therapeutics; 2013.</td></tr><tr><td valign="top" class="cellrightblue"><a name="713"> </a>713:</td><td class="cellleft">Harvoni [package insert]. Foster City,CA: Gilead Sciences; 2016.</td></tr><tr><td valign="top" class="cellrightblue"><a name="727"> </a>727:</td><td class="cellleft">Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Available at http://aidsinfo.nih.gov/contentfiles/lvguidelines/AdultandAdolescentGL.pdf.</td></tr><tr><td valign="top" class="cellrightblue"><a name="747"> </a>747:</td><td class="cellleft">Daklinza [package insert]. Princeton, NJ: Bristol-Myers Squibb Company, 2016</td></tr></table></div></div><div class="footer"><p class="footerlinks"><a href="InSite?page=About">About</a> | <a href="InSite?page=SM">Site Map</a> | <a href="fb?page=Feedback">Feedback</a> | <a href="InSite?page=Subscribe">Subscribe</a> | <a href="InSite?page=Donate">Donate</a> | <a href="InSite?page=Disclaimer">Disclaimer</a></p><p class="copyright"><a href="http://chi.ucsf.edu/" target="OffSite"><img src="images/footer/chi.gif" alt="UCSF - Center for HIV Information"/></a> HIV InSite is a project of the UCSF Center for HIV Information. Copyright 2017, Regents of the University of California.</p></div></div></body></html>